ZY OG1

Drug Profile

ZY OG1

Alternative Names: ZY-OG1

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Zydus Cadila
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2016 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in India (PO)
  • 11 Jul 2016 Discontinued - Phase-I for Obesity (In volunteers) in India (PO)
  • 08 Sep 2010 Phase-I clinical trials in Type-2 diabetes mellitus (in volunteers) in India (PO) (CTRI2010-091-000684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top